SUNLENCA

LENACAPAVIR SODIUM · Gilead Sciences, Inc.

Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for SUNLENCA, covering 2022-12-22 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children [Phase 2]

See pricing